| Overview |
| bs-8604R-PE |
| HLA B27 Polyclonal Antibody, PE Conjugated |
| WB |
| Human |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human HLA B27 |
| 81-180/362 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| HLA B27 HLA-B27; HLAB; Leukocyte antigen class I B; Lymphocyte antigen; Major histocompatibility complex class I B; SPDA1; 1B27_HUMAN. |
| Major histocompatibility complex (MHC) molecules form an integral part of the immune response system. They are cell-surface receptors that bind peptides and present them to T lymphocytes. Human leukocyte antigens (HLAs) are polymorphic members of the MHC family that are specifically involved in the presentation of antigens to the T cell receptor. There are two classes of HLA antigens: class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). Class I molecules are expressed in nearly all cells and play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum. The differential structural properties of MHC class I and class II molecules account for their respective roles in activating different populations of T lymphocytes. HLA-B encodes a membrane anchored heavy chain which hetero-dimerizes with a light chain (-2-Microglobulin) to form MHC-I. Polymorphisms yield hundreds of HLA-B alleles. The HLA-B27 allele appears with increased frequency in uveitis patients. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz